Sunny Pharmtech

Formed in 2005, the focus has been on the development of a 505(b)2 New Drug aimed at enhancing the life quality of cancer patients undergoing chemical and radiation treatments. Over 30 international patents have been approved for this innovative application. The initiation of oral and injectable generic drug advancement combined with API capabilities took place in 2011. Subsequently, in 2019, the production facility underwent successful inspections by TFDA and FDA. The seamless integration from API to finished Drug Product, complemented by expertise in chemistry, formulation, engineering, regulation, and project management, has secured Sunny's position as a specialty pharmaceutical company with global competitiveness.